Perfusion imaging of brain gliomas using arterial spin labeling: correlation with histopathological vascular density in MRI-guided biopsies

• DOI: 10.1007/s00234-016-1756-0
• Publication Date: 2016-12-06T08:03:53Z
• Authors: Di Ningning; Pang Haopeng; Dang Xuefei; Cheng Wenna; Ren Yan; Wu Jingsong; Yao Chengjun; Yao Zhenwei; Feng Xiaoyuan
• Keywords: Adult; Gadolinium DTPA; Image-Guided Biopsy; Male; Neovascularization, Pathologic; Brain Neoplasms; Microcirculation; Contrast Media; Glioma; Middle Aged; 03 medical and health sciences; Imaging, Three-Dimensional; 0302 clinical medicine; Cerebrovascular Circulation; Image Interpretation, Computer-Assisted; Humans; Female; Spin Labels; Neoplasm Grading; Magnetic Resonance Angiography; Aged; Retrospective Studies

This study was designed to determine if cerebral blood flow (CBF) derived from arterial spin labeling (ASL) perfusion imaging could be used to quantitatively evaluate the microvascular density (MVD) of brain gliomas on a "point-to-point" basis by matching CBF areas and surgical biopsy sites as accurate as possible.The study enrolled 47 patients with treatment-naive brain gliomas who underwent preoperative ASL, 3D T1-weighted imaging with gadolinium contrast enhancement (3D T1C+), and T2 fluid acquisition of inversion recovery (T2FLAIR) sequences before stereotactic surgery. We histologically quantified MVD from CD34-stained sections of stereotactic biopsies and co-registered biopsy locations with localized CBF measurements. The correlation between CBF and MVD was determined using Spearman's correlation coefficient. P ≤ .05 was considered statistically significant.Of the 47 patients enrolled in the study, 6 were excluded from the analysis because of brain shift or poor co-registration and localization of the biopsy site during surgery. Finally, 84 biopsies from 41 subjects were included in the analysis. CBF showed a statistically significant positive correlation with MVD (ρ = 0.567; P = .029).ASL can be a useful noninvasive perfusion MR method for quantitative evaluation of the MVD of brain gliomas.